The major cause of treatment failure following allogeneic bone marrow transplantation for acute leukaemia is disease relapse. In an attempt to reduce posttransplant relapse in 33 children with high-risk acute leukaemia who received a related or unrelated bone marrow transplant, the pre-transplant conditioning regimen was intensified by the addition of idarubicin. Its toxicity and effects on survival were evaluated over a 57-month period. Toxicity, largely gastrointestinal, was increased but acceptable, and there was no specific regimen-related toxicity. Relapse rates were low (24%) in this high risk group, but mortality was increased in those receiving unrelated donor grafts, largely due to sepsis. Idarubicin does appear to have a role to play in the conditioning regimen of patients with high-risk acute leukaemia undergoing BMT, and may reduce relapse rates without increasing transplant-related mortality. Keywords: childhood acute leukaemia; idarubicin; BMT Acute leukaemias are rare in children, and represent onethird of all childhood malignancies. In children with high-risk acute leukaemia in either first or other remission, prognosis is poor. Intensive treatment including allogeneic bone marrow transplantation may offer the best chance of long-term disease-free survival.
Acute leukaemias are rare in children, and represent onethird of all childhood malignancies. In children with high-risk acute leukaemia in either first or other remission, prognosis is poor. Intensive treatment including allogeneic bone marrow transplantation may offer the best chance of long-term disease-free survival. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Leukaemic recurrence however, continues to play a major role in treatment failure.
One possible way of reducing the probability of relapse is to further intensify the conditioning regimen prior to transplantation using anthracyclines which have proven anti-leukaemic activity, provided this approach is not associated with unacceptable toxicity and increased procedurerelated mortality. [14] [15] [16] Two pilot studies have demonstrated a reduction in relapse rates, improved disease-free and actuarial survival with comparable transplant-related mortality in patients receiving intensified conditioning with idarubicin prior to sibling T cell-depleted grafts when compared with historical controls. 14, 15 In 1993, Muus et al 17 studied different schedules of administration of idarubicin in inten-sified conditioning regimens in a heterogeneous population of patients with malignant haematological disease. They also demonstrated reduced relapse probability, increased overall and disease-free survival without increased transplant-related mortality in comparison with historical controls receiving cyclophosphamide and total body irradiation (TBI) alone, prior to a T cell-depleted graft. The toxicity of the intensified regimen was schedule-dependent and was reduced by administration of idarubicin earlier in the conditioning regimen.
We report the use of an intensified conditioning regimen containing idarubicin in 33 children considered to be at high risk of leukaemic relapse. We discuss the toxicity of the regimen and its success with respect to relapse and mortality.
Patients and methods
Between April 1994 and March 1997, 33 children with high risk acute leukaemia received an intensified conditioning regimen prior to allogeneic bone marrow transplantation at Birmingham Children's Hospital. Clinical characteristics are detailed in Table 1 . Patients were considered at high risk of relapse due to the presence of one or more poor prognostic factors, detailed in Table 2 .
Seventeen of the 33 patients received matched/partially mismatched unrelated transplants, three partially mismatched parental grafts and 13 matched/partially mismatched sibling grafts. All patients aged over 2 years (n = 30) received conditioning with idarubicin 21 mg/m 2 daily as a continuous i.v. infusion over 48 h on days −12 and −11 (total dose 42 mg/m 2 ), fractionated TBI 14.4 Gy in eight fractions on days −7 to −4 with cranial and/or testicular boosts as appropriate, and cyclophosphamide 60 mg/kg once daily on days −3 and −2 (total dose 120 mg/kg). One patient in this group received a lower dose of idarubicin (10 mg/m 2 daily for 2 days) as an echocardiogram had shown reduced left ventricular function.
Patients aged less than 2 years (n = 3) received the same regimen but TBI was replaced with busulphan 4 mg/kg orally in divided doses daily for 4 days on days −9 to −6 (total dose 16 mg/kg). Additional doses were given if plasma busulphan levels were suboptimal. All patients received GVHD prophylaxis with cyclosporin A (2.5 mg/kg twice daily) commencing on day −1, and continuing for a minimum of 3 months in the absence of GVHD. All recipients of unrelated grafts also received either Campath or anti-lymphocyte globulin (ALG) 12.5 mg/kg daily. These were generally given for a duration of 5 days pre-transplant in those receiving T cell-depleted grafts and for 5 days preand 5 days post-transplant for those receiving non-T celldepleted grafts. One recipient of a parental graft and one of a sibling graft also received Campath and ALG respectively, due to the degree of HLA mismatch.
Prior to August 1995 all MUD transplants were T celldepleted (n = 11). Due to the potential increased risk of relapse this manipulation was abandoned after this date (n = 6). No parental or sibling grafts were T cell-depleted.
CMV prophylaxis was with acyclovir (10 mg/kg three times daily i.v. or 500 mg/m 2 three times daily i.v. according to donor and recipient CMV status) and intravenous immunoglobulin (0.4 g/kg once weekly). These were given to 100 days post-transplant unless there was persistent GVHD, when prophylaxis was continued. Antifungal prophylaxis was with daily oral fluconazole, antibacterial Table 2 High risk features at transplantation
Risk feature Number of patients
Early relapse (on or within 6 months of finishing therapy) 15 Failure to remit by day 28 11 Infantile ALL (t(4;11)) 3 Unfavourable cytogenetics 2 (t(9;22); hypodiploid) Third remission 1 ALL with combined BM/CNS/testicular relapse 11 months 1 off treatment T cell ALL with CNS and testicular disease and 1 WCC Ͼ100 × 10 9 /l AML, second remission 2 ALL = acute lymphoblastic leukaemia; BM = bone marrow; CNS = central nervous system; WCC = white cell count.
prophylaxis with ciprofloxacin and mouth care with chlorhexidine mouth wash. Broad spectrum antibiotics were given in the event of fever, with liposomal amphotericin being added if fever persisted or there was suggested or documented fungal infection. All patients were nursed in air filtered rooms with reverse barrier nursing, and a non-microbial sterile diet.
Granulocyte colony-stimulating factor (lenograstim 0.5 MIU/kg daily) was commenced on day +8 and continued daily until engraftment. Total parenteral nutrition was given to those unable to tolerate enteral feeding.
Prior to transplantation all patients had an echocardiogram to measure left ventricular ejection fraction and fractional shortening. An ejection fraction of Ͼ50% was required to receive full-dose idarubicin.
Toxicity of the regimen, time to engraftment, occurrence of acute and chronic GVHD and its treatment, duration of hospital stay, occurrence of graft failure, relapse and mortality were examined retrospectively from case notes.
Engraftment was defined as a neutrophil count of Ͼ0.5 × 10 9 /l for 3 consecutive days. Mucositis was scored according to WHO criteria as mild, moderate or severe, and its duration from the first onset of symptoms to complete resolution. Gut toxicity was scored according to the severity of diarrhoea (Ͻ1000 ml/day, mild; 1000-1500 ml/day, moderate; Ͼ1500 ml/day, severe). Transplant-related mortality was defined as occurring within 100 days from the day of transplant.
Results
The results of this study can be grouped according to disease-free survival and the complications of the bone marrow transplant procedure. Follow-up is to February 1999, with a range of 23 to 57 months (mean 39 months).
Relapse (Table 3)
Eight patients have relapsed (24%) at a follow-up of up to 57 months, seven of whom have died. The time to relapse post-BMT ranged from 5 to 24 months. The relapse rate for MUD/parental grafts is 30% (6/20) and for sibling grafts 15% (2/13). All four relapses in recipients of unrelated donor transplants had received T cell-depleted grafts.
Toxicity
Oral mucositis: All patients experienced mucositis. This was severe in 24/33 (73%), and moderate in 9/33 (27%). Recipients of sibling grafts were more likely to develop severe mucositis than those receiving MUD/parental grafts (92% vs 60%). The mean duration of mucositis in all patients was 17.3 days (range 8-29 days), and was of shorter duration in those receiving sibling grafts (mean 15.4 days vs 18.6 days). None of the recipients of sibling grafts received methotrexate and the reason for the increased incidence but reduced duration of severe mucositis in this group is unclear. All patients required analgesia with intravenous opiates (morphine sulphate), administered either as a continuous infusion, or as patient controlled analgesia 955 Table 3 Relapse (PCA). The severity of mucositis and requirement for opiate analgesia in this group of patients appeared, in our experience, to be increased compared to those receiving conventional conditioning (unpublished observations).
Diagnosis
Gut toxicity: Thirty patients (91%) experienced gut toxicity in the form of diarrhoea, although in the majority (82%) this was mild. The mean duration of diarrhoea was 13 days (range 2-44 days), and was shorter in sibling than in nonsibling grafts (mean 9.8 days vs 14.8 days). The severity of gut toxicity in these patients appears to be comparable to that seen in patients receiving non-idarubicin containing regimens in our centre.
Regimen-related toxicity:
There was no specific regimenrelated toxicity. Hypertension and fluid overload occurred in patients receiving cyclosporin A in combination with high-dose glucocorticoids. The occurrence of renal failure was multifactorial involving a combination of sepsis, nephrotoxic agents and hypotension as precipitating factors. Hepatic veno-occlusive disease occurred in two patients, neither of whom had received busulphan. One patient developed autoimmune haemolytic anaemia following an ABO mismatched transplant. Erythema multiforme occurred in association with administration of ALG and resolved spontaneously. There was no excess cardiotoxicity, and patients experiencing left ventricular failure did so secondary to fluid overload and sepsis, with normalisation of cardiac function on echocardiogram after the acute event.
Time to engraftment
The mean time to engraftment for all patients was 16 days (range 11-29 days). This was longer for MUD/parental grafts than for sibling grafts (16.7 days vs 15.1 days). This is comparable to patients receiving non-idarubicin-containing regimens in our centre.
Graft-versus-host disease
Acute GVHD occurred in 28/32 (87.5%) evaluable patients (one patient was not evaluable for GVHD as death occurred 1 week post-BMT). Of these 28, eight had grade I (MUD/parental 5; sibling 3), 12 grade II (MUD/parental 8; sibling 4), four grade III (sibling 4) and four grade IV (MUD/parental 2; sibling 2) GVHD. Thus, the majority of patients (75%) had either no or only mild-moderate grade I-II GVHD. Recipients of sibling grafts had more severe GVHD than recipients of MUD/parental grafts with 46% having grade III-IV, cf 11%. Amongst the unrelated grafts, GVHD occurred in recipients of both T and non-T celldepleted grafts. All but four patients required immunosuppressive therapy. Five patients developed chronic GVHD (MUD/parental 3; sibling 2) requiring prolonged immunosuppressive therapy.
Supportive treatment
All patients required treatment with broad spectrum intravenous antibiotics for febrile episodes. 29/33 (88%) patients required parenteral nutrition. Enteral feeding was attempted in all patients but was frequently not tolerated, mainly due to diarrhoea.
Hospital stay
Mean hospital stay was 52 days (range 34-91 days). Duration of hospital stay was longer in recipients of MUD/parental grafts than in those receiving sibling grafts (54.6 days vs 48.5 days). Hospital stay appears to be increased in these patients when compared to patients receiving non-intensified conditioning regimens in our centre.
Graft failure
Four patients (12%) experienced graft failure, and all were recipients of MUD transplants. Two were primary graft failures, both T cell-depleted. One of these patients received an autologous graft and remains in complete remission. The other received a second non-T cell-depleted unrelated graft which also failed, followed by an autograft. He died secondary to sepsis whilst awaiting autologous engraftment.
One patient showed weak engraftment of a T celldepleted graft and then rejected at 2 months. He received a second non-T cell-depleted graft which also failed, followed by an autologous graft. Engraftment again failed and the patient died at 3 months following the first MUD transplant.
The fourth patient experienced failure of a T celldepleted graft at 7 months, followed by autologous reconstitution and maintenance of complete remission. This patient has since had a molecular relapse, received a second MUD, and remains in remission.
Mortality
Follow-up is between 23 and 57 months. Twenty of the 33 patients have died, giving an overall mortality of 61%. Overall mortality was considerably higher in the non-sibling transplant group (75% vs 38%). Of the 20 deaths, eight were transplant-related (within 100 days of transplant) and 12 were non-transplant-related.
Transplant-related mortality was 24% and was comparable in the two groups. The causes of transplant-related mortality were sepsis in four patients, acute GVHD in three and GI bleed in one.
Non-transplant-related mortality was 48% (12) , and was higher in recipients of MUD/parental grafts than in those receiving sibling grafts. The causes of death were relapse in seven (MUD/parental 5; sibling 2), and sepsis in five (all MUD grafts, both T and non-T cell-depleted).
Thirteen patients remain alive (39%) and of these 11 remain in remission (33%), four MUD/parental transplants (20%) and seven sibling grafts (54%).
Discussion
This study has examined the use of idarubicin in the conditioning regimen of allogeneic transplantation for children with high risk acute leukaemia and evaluated toxicity, relapse and survival.
Idarubicin was introduced in 1990 and has been successfully used in a variety of haematological malignancies, including newly diagnosed acute leukaemias, refractory and relapsed leukaemia, and myelodysplasia in both adults and children. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In randomised trials it has been compared with daunorubicin in the treatment of de novo adult AML, and has been shown to be associated with increased remission rates and survival. [30] [31] [32] With respect to toxicity, idarubicin appears to be qualitatively similar to other anthracyclines, although some studies suggest it may be more myelosuppressive and produce greater gastrointestinal toxicity. Cardiotoxicity does not appear to be increased. Idarubicin may also be less sensitive to expression of the multidrug resistance (MDR) phenotype in comparison to other anthracyclines.
16-19,22-26,28-34
The apparent superior cytotoxicity without enhanced toxicity led to idarubicin being chosen to intensify conditioning prior to BMT in two pilot studies. These demonstrated a significant reduction in relapse rates, increase in diseasefree survival and actuarial survival, with comparable transplant-related mortality when compared to historical controls receiving standard conditioning.
14, 15 Muus et al 17 studied different schedules of administration of idarubicin and demonstrated similar results with respect to relapse and survival. They found that the toxicity of the intensified regimen was schedule-dependent and could be reduced by administration of idarubicin earlier in the conditioning on days −12 and −11.
In the current study, 33 children with high risk acute leukaemia received an intensified conditioning regimen with idarubicin prior to allogeneic bone marrow transplantation in addition to conventional conditioning with cyclophosphamide and total body irradiation or busulphan. Although the study was not randomised several observations can be made on the use of idarubicin in this situation.
Toxicity associated with this regimen was marked but acceptable. The main toxicities were mucositis and diarrhoea. There was no specific regimen-related toxicity, and in particular no cardiotoxicity was seen in this group of patients, all of whom had previously received anthracyclines. As reported by Muus et al 17 there does not appear to be any delay in engraftment compared to non-idarubicincontaining regimens. As already mentioned there was no randomisation in this study, but comparison with historical cases suggests that the use of idarubicin increased toxicity, particularly mucositis.
There was a high incidence of acute graft-versus-host disease, although in the majority it was only grade I-II. This frequency is perhaps surprising given that many of the grafts were T cell-depleted, but may be related to the high incidence of gastrointestinal toxicity and mucositis. Recipients of sibling grafts experienced more severe GVHD (grade III-IV) than those receiving MUD/parental grafts (46% vs 11%). The reason for this is uncertain, but may have been due to increased vigilance and subsequent early treatment in the MUD/parental group. The incidence of acute GVHD appears to be higher in patients receiving intensified conditioning than in those receiving conventional conditioning in our centre (unpublished observations).
The graft failure rate observed in this study is comparable with our experience using non-idarubicin-containing conditioning regimens.
The relapse rate of 24% reported here is low and comparable to a relapse rate of 17% reported in the idarubicincontaining regimen used by Muus et al 17 which included standard as well as high risk patients. It is possible that a higher relapse rate has been masked by the septic deaths encountered in this study. Seven of these relapsed patients have died. One is alive and in remission after a second non-T cell-depleted unrelated transplant.
The overall mortality in this group of patients was 61% and reflects the high risk children studied. The causes of mortality show significant differences between the different transplant groups. Transplant-related mortality was compa-rable in MUD/parental grafts and sibling grafts, and compares favourably with a transplant-related mortality of 25% reported by Muus et al. 17 Non-transplant-related mortality however, was considerably higher in the MUD/parental group than in the sibling grafted group. The causes of nontransplant-related mortality were relapse and sepsis. Relapse deaths occurred in both groups, but in the unrelated group only occurred in those receiving T cell-depleted grafts. Septic deaths were only seen with unrelated grafts (both T and non-T cell-depleted). These episodes of sepsis occurred between 3 and 10 months post-BMT, progressing to multiorgan failure and death. Two of the deaths occurred in patients without GVHD or additional risk factors for sepsis. One patient was awaiting engraftment of an autologous transplant, following rejection of both a T cell-depleted and a second non-T cell-depleted unrelated graft. The two other deaths were in patients with chronic GVHD receiving immunosuppressive therapy. Late infectious complications are known to be a major cause of morbidity and mortality after allogeneic transplantation, with a greater incidence in unrelated transplants and in patients with chronic GVHD. 35, 36 Aggressive surveillance and perhaps prolonged antibiotic prophylaxis is therefore indicated for recipients of unrelated grafts and those with chronic GVHD.
In conclusion, intensification of the conditioning regimen prior to allogeneic BMT using idarubicin has increased, but acceptable, toxicity in this group of children with high-risk acute leukaemia. Non-transplant-related and overall mortality however, were high in the unrelated group. This is in part due to relapse following T cell depletion, a procedure which is no longer performed. However, one of the major causes of non-transplant-related mortality was sepsis. This is of concern and indicates the need for increased vigilance in those patients with prolonged immunosuppression.
Idarubicin may have a role to play in conditioning of patients with high-risk acute leukaemia undergoing bone marrow transplantation. It appears to reduce relapse rates and thus increase disease-free survival, without increasing transplant-related mortality. Care however, needs to be taken in the unrelated setting in view of the increased mortality seen in this study. We are currently reviewing the results of a modified intensified conditioning regimen, where idarubicin is administered 4 weeks prior to transplantation, followed by autologous peripheral blood stem cell rescue, and then standard conditioning with TBI and cyclophosphamide to see if this approach can further reduce toxicity whilst maintaining the low relapse rates reported in this study. This type of approach of intensified conditioning prior to transplantation in high risk patients needs to be assessed in a randomised study in a larger group of patients.
